Kartalci et al., 2016 [41] reported a significant increase in serum concentrations of IL-4 and TGF-β1 post-ECT in comparison to pre-ECT, and also a correlation between this effect and a clinical improvement (decrease of schizophrenia symptoms) in TRS patients. The gene discussed is TGFB1; the disease is schizophrenia.